REDWOOD CITY, Calif.,
Nov. 26, 2013 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute and breakthrough
pain, today announced that Richard
King, President and CEO, will present a corporate overview
at the 25th Annual Piper Jaffray Healthcare Conference
at the New York Palace in New
York, NY. The presentation is scheduled for
Wednesday, December 4, 2013 at
10:00 a.m. ET/7:00 a.m. PT.
The presentation will be webcast live and can be accessed
through the Investors page at www.acelrx.com. For those not
available to listen to the live broadcast, a replay of the
presentations will be archived for 90 days and available through
the Investors page on www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute and breakthrough
pain. AcelRx's lead product candidate, Zalviso, is designed
to solve the problems associated with post-operative intravenous
patient-controlled analgesia which has been shown to cause harm to
patients following surgery because of the side effects of morphine,
the invasive IV route of delivery and the complexity of infusion
pumps. AcelRx has announced positive results from each of the
three Phase 3 clinical trials for Zalviso and has submitted an NDA
to the FDA seeking its approval. AcelRx has also announced
positive top-line results for a Phase 2 trial for ARX-04, a
sufentanil formulation for the treatment of moderate-to-severe
acute pain, funded through a grant from the U.S. Army Medical
Research and Materiel Command. The company has two additional
pain treatment product candidates, ARX-02 and ARX-03, which have
completed Phase 2 clinical development. For additional
information about AcelRx's clinical programs, please visit
www.acelrx.com.
Forward Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to planned or
anticipated future clinical development of AcelRx Pharmaceuticals'
product candidates, and the therapeutic potential of AcelRx
Pharmaceuticals' product candidates. These forward-looking
statements are based on AcelRx Pharmaceuticals' current
expectations and inherently involve significant risks and
uncertainties. AcelRx Pharmaceuticals' actual results and the
timing of events could differ materially from those anticipated in
such forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks related to:
the success, cost and timing of AcelRx Pharmaceuticals' product
development; the market potential for its product candidates; and
other risks detailed in the "Risk Factors" and elsewhere in AcelRx
Pharmaceuticals' U.S. Securities and Exchange Commission filings,
including its Quarterly Report on Form 10-Q filed with the SEC on
November 5, 2013. AcelRx
Pharmaceuticals undertakes no duty or obligation to update any
forward-looking statements contained in this release as a result of
new information, future events or changes in its expectations.
(Logo:
http://photos.prnewswire.com/prnh/20130226/MM67303LOGO)
SOURCE AcelRx Pharmaceuticals, Inc.